NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1211.40 10.60 (0.88%)

2.5M NSE+BSE Volume

NSE 08 Aug, 2025 3:31 PM (IST)

101,101.2

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

30 Jul 2019

1211.40

0.88%

Dr Reddy's Laboratories

Hold: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

US going through rough patch but promising launches ahead Despite a challenging time, US remains a key driver for the company, contributing ~42% to total revenues. The company has a strong pending pipeline comprising 104 (58 Para IV filings, 34 FTFs) and three NDAs under 505 (b)(2) route. We expect US sales to grow at a CAGR of 11% to | 7395...

Deven Choksey released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1120.0 on 29 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

30 Jul 2019

1211.40

0.88%

Dr. Reddys Laboratories: Margins move up on back of settlement income

Buy: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Karvy

Dr. Reddys Lab (DRL) revenue, increased by 3.3% YoY to Rs 38.4 bn, is lower than our estimates of Rs 41.2 bn; primarily due to good growth in Domestic, Europe and Emerging market business.

Deven Choksey released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1120.0 on 29 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

29 Jul 2019

1211.40

0.88%

Q1FY20 Result Update

Accumulate: Dr. Reddy's Laboratories Ltd.

Prabhudas Lilladhar

DRRD sales were in line with our estimates while adj. EBITDA and adj. PAT Change in Estimates | Target | Reco missed estimates due to significantly lower PSAI sales, one-off inventory adjustment and price erosion in key generics. Management however...

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

29 Jul 2019

1211.40

0.88%

Dr Reddy's Labs (ADD): Adj. EBITDA in line; upgrade to ADD on reasonable valuations

Dr. Reddy's Laboratories Ltd.

BOB Capital Markets Ltd.

Q1 reported 18% EBITDA miss impacted by one-offs in gross margins (PSAI & inventory write-offs in US totaling US$20mn, in my view), while adj. EBITDA was in line.

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

14 Jun 2019

1211.40

0.88%

Result Update:Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

Dr. Reddy's Lab. (DRRD) demonstrated mixed performance in Q4FY19, with revenue stood at Rs 4,017cr (vs. estimate of Rs 3,840cr), beat was on the back of one-time revenue realized from the sale of derma brands of Rs180cr.

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

20 May 2019

1211.40

0.88%

Dr Reddy's Laboratories

Hold: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

US going through rough patch but promising launches ahead Despite challenging years, the US remains a key driver for the company, contributing ~42% to total revenues. The company has strong pending pipeline comprises 110 (60 Para IV filings and 43 FTFs) including three NDAs under 505 (b)(2) route. We expect US sales to grow at a CAGR of 10% to...

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

20 May 2019

1211.40

0.88%

Dr. Reddys Lab: Margins move up on back of lower SG&A; and R & D

Hold: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Karvy

Dr. Reddys Lab's (DRL) revenue, increased by 13.6% YoY to Rs40.2 bn, ishigher than our estimates of Rs 38.9bn; primarily due to good growth inEurope and Emerging market business.

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

19 May 2019

1211.40

0.88%

Dr. Reddy's Labs (4QFY19): Not to be missed. Maintain BUY

Buy: Dr. Reddy's Laboratories Ltd.

Target

HDFC Securities

Coming out of a regulatory debacle and two years of dismal operational performance, DRRD ended the year with 8/40/77% revenue/EBITDA/PAT growth respectively. With a sharp focus on cost optimization, weeding out of non-profitable businesses, largely clean regulatory slate, improving balance sheet and a major US revival, we remain constructive on DRRD. We believe it will be the best performing pharma stock in FY20E. To our surprise, DRRD is also catching up fast on biosimilar filings for developed markets (bNeulasta expected in 1HFY20). China ramp up remains another interesting opportunity. Overall, we expect 16/22/18% revenue/EBITDA/PAT CAGR over FY19-21E. At 22/19x FY20/21E EPS, the valuations remain attractive as compared to peers. We maintain BUY on DRRD despite a miss on our estimates (on account of certain one-offs). Our TP is revised to Rs 3,320/sh (20x FY21E EPS + Rs 380/sh for niche products). The focus on cost optimization and a revival in the US biz are key to our thesis.

Deven Choksey released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1120.0 on 29 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

19 May 2019

1211.40

0.88%

Q4FY19 Result Update

Hold: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

DRRD's sales and adj. EBITDA are in line with our estimates while adj. PAT was a miss in our estimates by 11% due to low other income and high tax outgo (rate). While its gross margin declined by 90bps QoQ, its rationalized overhead costs (SGA and R&D;) cited benefits of organizational restructure in the recent past. SGA overhead increased by only 4%, while R&D; costs were flat QoQ. Management maintains its guidance of focus on productivity, rationalized product portfolio, new products and foraying new markets in FY20E and FY21E. Also, EBITDA margin decreased by 50bps QoQ due to...

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

18 May 2019

1211.40

0.88%

Price erosion/higher cost hurt earnings; Execution remains the key

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

revenue is up 8.5% YoY to INR38.4b. The overall growth was dragged to some extent by 3% YoY growth in US sales (INR15b) and moderate 6%/8% YoY growth in domestic/PSAI sales to INR6.5b/INR6.8b Inferior product mix and manufacturing overheads impact profitability: Adjusting for the one-time sale of its derma brands, gross margin (GM) declined ~330bp YoY (-90bp QoQ) to 50.2%, primarily due to competition in key products, higher manufacturing overheads, impact of inventory management and adverse currency movement. Although GM contracted,...

Deven Choksey released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1120.0 on 29 Jul, 2025.

Is Dr. Reddy's Laboratories Ltd. worth buying?

519 Votes:

Buy 78.23%

Sell 12.14%

Hold 9.63%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf